CanBas Co Ltd Information

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. The company develops CBP501, a calmodulin modulator for the treatment of tumors. It also develops CBS9106, a small molecule reversible inhibitor of Exportin-1 that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was founded in 2000 and is based in Numazu, Japan.

Website	http://www.canbas.co.jp/
Ticker	TYO:4575
Revenue	$7 million
Employees	5 (0 on RocketReach)
Founded	2000
Address	2-2-1 Otemachi, Numazu, Shizuoka 410-0801, JP
Phone	+81 55-954-3666
Fax	+81 55-954-3668
Technologies	JavaScript , HTML , PHP +9 more (view full list)
Industry	Manufacturing General, Biopharma, Drug Discovery, Manufacturing, Biotechnology, Pharmaceuticals, Health Care, Science and Engineering, Therapeutics
Keywords	Cancer Therapeutics, Cancer Research, Biotechnology, Tumor Treatment, Cancer Drugs, Biopharmaceutical, Drug Development, Pharmaceutical Research, Targeted Therapy, Drug Discovery, Oncology, Clinical Stage, Novel Therapeutics, Clinical Trials, Medicinal Chemistry
Competitors	CMA CGM, Hapag-Lloyd AG, ZIM Integrated Shipping Services, NYK Line, Yang Ming Marine Transport Corp., 韩进海运(中国)有限公司, Evergreen Marine Corp. Ltd, Mitsui O.S.K. Lines, Ltd., K Line New York Inc, Shipping.com LLC +38 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies